---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-149302"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T19:55:24.954183+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amneal settles derivative suit over KSP acquisition; royalty cut, governance changes

## Summary
- Amneal agreed to reduce Kashiv royalties by 1.15% on three products until $11.5M NPV cap is reached.
- Attorneys' fees capped at $2M, subject to court approval; settlement hearing set for July 25, 2023.
- Governance changes include independent Delaware counsel for related-party transactions and stockholder vote on deals >$100M.
- Deborah M. Autor added to Amneal board and Conflicts Committee as independent director.
- Settlement resolves claims that 2021 KSP acquisition was unfair; no admission of wrongdoing.

## SEC filing metadata
- accession: 0001193125-23-149302
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000119312523149302/0001193125-23-149302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000119312523149302/d484910d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-149302
- JSON: https://secwatch.observer/filing/0001193125-23-149302.json
- Plain text: https://secwatch.observer/filing/0001193125-23-149302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.